**Core Concept**
The treatment of postmenopausal osteoporosis involves a variety of pharmacological agents aimed at reducing bone resorption and increasing bone formation. **Hormone replacement therapy (HRT)**, **bisphosphonates**, **selective estrogen receptor modulators (SERMs)**, and **parathyroid hormone analogs** are commonly used.

**Why the Correct Answer is Right**
Since the correct answer is not provided, let's discuss the general approach to treating postmenopausal osteoporosis. Drugs like **alendronate** (a bisphosphonate), **raloxifene** (a SERM), and **teriparatide** (a parathyroid hormone analog) are used to treat osteoporosis by either inhibiting bone resorption or stimulating bone formation.

**Why Each Wrong Option is Incorrect**
**Option A:** Without the specific drug, it's challenging to provide a precise explanation, but typically, options that are incorrect in this context might include drugs that are not primarily used for osteoporosis treatment or those that could exacerbate the condition.
**Option B:** Similarly, without the specific drug, we can't determine why it's incorrect, but it might be a drug that's not indicated for osteoporosis or has significant side effects that outweigh its benefits in this context.
**Option C:** Again, lacking the specific drug, we can speculate that it might be incorrect due to lack of efficacy in treating osteoporosis or due to adverse effects.
**Option D:** This option, like the others, would be incorrect based on its lack of efficacy or safety profile in the treatment of postmenopausal osteoporosis.

**Clinical Pearl / High-Yield Fact**
A key point in treating postmenopausal osteoporosis is to consider the patient's overall health, including her risk of fracture and her tolerance for potential side effects of the medication. **Bisphosphonates** are a common first-line treatment due to their efficacy in reducing fracture risk.

**Correct Answer:** Correct Answer: D. Glucocorticoids.